{"id":"bivalirudin-with-and-without-eptifibatide","safety":{"commonSideEffects":[{"rate":"5-15%","effect":"Bleeding (major and minor)"},{"rate":"1-3%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"2-5%","effect":"Bradycardia"},{"rate":"5-10%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Bivalirudin directly binds to and inhibits thrombin, a key enzyme in the coagulation cascade, preventing fibrin formation and clot propagation. Eptifibatide blocks the glycoprotein IIb/IIIa receptor on platelets, preventing platelet aggregation. Together, this combination provides comprehensive anticoagulation and antiplatelet effects for acute coronary syndromes and percutaneous coronary intervention.","oneSentence":"Bivalirudin is a direct thrombin inhibitor that prevents blood clot formation, and when combined with eptifibatide (a glycoprotein IIb/IIIa inhibitor), provides dual antiplatelet and anticoagulant effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:40:33.700Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute coronary syndrome (unstable angina, NSTEMI, STEMI) undergoing percutaneous coronary intervention"},{"name":"Prevention of thrombotic complications during coronary angioplasty"}]},"trialDetails":[{"nctId":"NCT01087723","phase":"PHASE3","title":"European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2010-03","conditions":"Acute Coronary Syndrome","enrollment":2198},{"nctId":"NCT00370045","phase":"PHASE4","title":"Peri-Procedural Myocardial Infarction, Platelet Reactivity, Thrombin Generation, and Clot Strength: Differential Effects of Eptifibatide + Bivalirudin Versus Bivalirudin","status":"UNKNOWN","sponsor":"LifeBridge Health","startDate":"2006-03","conditions":"Coronary Artery Disease","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":46,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Bivalirudin with and without eptifibatide","genericName":"Bivalirudin with and without eptifibatide","companyName":"LifeBridge Health","companyId":"lifebridge-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Bivalirudin is a direct thrombin inhibitor that prevents blood clot formation, and when combined with eptifibatide (a glycoprotein IIb/IIIa inhibitor), provides dual antiplatelet and anticoagulant effects. Used for Acute coronary syndrome (unstable angina, NSTEMI, STEMI) undergoing percutaneous coronary intervention, Prevention of thrombotic complications during coronary angioplasty.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}